Risk Assessment for Potential Elemental Impurities on Drug Products/Medical Devices
When Drug Products were submitted for approval, Regulatory authorities ask the question, “Are you submitting your Risk Assessment for the Potential Elemental Impurities as well?”.
This webinar will address how to deal with “Risk Assessment for Potential Elemental Impurities” on Drug Products and Medical Devices. The USP, in parallel with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), has published standards for measuring inorganic impurities in pharmaceuticals and their ingredients. The USP General Chapters USP 232 (Elemental Impurities – Limits) and 233 (Elemental Impurities – Procedures) were implemented as of January 2018. The equivalent ICH method was defined in the Guideline for Elemental Impurities (Q3D) and Revision 1 was adopted on March, 2019. The ICH Q3D and USP 232 chapters include catalyst elements, and other inorganic contaminants that may enter a drug product from raw materials, the manufacturing process, the environment, packaging and container closure systems (CCS). The maximum exposure limits are defined according to each impurity's toxicity and route of exposure.
What you will learn in this webinar:
• Learn the concept of risk assessment for potential elemental impurities
• How Potential Elemental Impurities on Drug Products/Medical Devices are regulated.
• Get expert insights on how to develop methodologies regarding Elemental Impurities on Drug Products/Medical Devices via ICP-MS.
Видео Risk Assessment for Potential Elemental Impurities on Drug Products/Medical Devices канала Nelson Labs
This webinar will address how to deal with “Risk Assessment for Potential Elemental Impurities” on Drug Products and Medical Devices. The USP, in parallel with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), has published standards for measuring inorganic impurities in pharmaceuticals and their ingredients. The USP General Chapters USP 232 (Elemental Impurities – Limits) and 233 (Elemental Impurities – Procedures) were implemented as of January 2018. The equivalent ICH method was defined in the Guideline for Elemental Impurities (Q3D) and Revision 1 was adopted on March, 2019. The ICH Q3D and USP 232 chapters include catalyst elements, and other inorganic contaminants that may enter a drug product from raw materials, the manufacturing process, the environment, packaging and container closure systems (CCS). The maximum exposure limits are defined according to each impurity's toxicity and route of exposure.
What you will learn in this webinar:
• Learn the concept of risk assessment for potential elemental impurities
• How Potential Elemental Impurities on Drug Products/Medical Devices are regulated.
• Get expert insights on how to develop methodologies regarding Elemental Impurities on Drug Products/Medical Devices via ICP-MS.
Видео Risk Assessment for Potential Elemental Impurities on Drug Products/Medical Devices канала Nelson Labs
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
The Future of Biocompatibility Testing Might Just be Animal Free!Cleaning Validation Roadmap for Reusable Medical DevicesBiocompatibility Evaluation for Device SubmissionStrategies for Testing Hemocompatibility and Potential Upcoming ChangesCleaning Validations for Reusable Medical Devices & FDA Test TrendsHow to Use Biocompatibility to Evaluate Changes in a Medical DeviceSatisfying ISO 18562 and FDA Biocompatibility Requirements for Breathing Gas Pathways DevicesIf something looks clean, is it really clean? Cleaning validations for reusable devicesEvaluating the biocompatibility of reusable medical devices during their whole life cycleShortages of critical raw materials and managing changes and substitutions - Dennis JenkeAddressing Common Observations in Regulatory Submissions of Chemical Characterization ResultsPackage Validations – Meeting the Requirements of ISO 11607STEM UtahWISE Scientist Stories Megan MoffatDeveloping Contamination Control StrategyThe need for a higher level of identifications in large volume parenteral packaging qualificationsThe production process and qualification of film: A film manufacturer perspectiveA Guide to Emergency Use Authorization of Gas Path DevicesAppropriate uses for Product Sterility Testing – when is sterility testing appropriateUnknowns, TICs, and Identified Compounds Below the TTC